Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With HER2-negative, ER and/or PgR Positive Metastatic Brest Cancer With Progressive Disease After First-line Therapy

NCT01477060 is registered in ClinicalTrials.gov with Fondazione Michelangelo as lead sponsor.

NCT NCT01477060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01477060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With HER2-negative, ER and/or PgR Positive Metastatic Brest Cancer With Progressive Disease After First-line Therapy
Lead sponsor
Fondazione Michelangelo
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2011
Completion date
December 31, 2013
Enrollment
32 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer